Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15823736 | 0.94 | POLB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2899450 | 0.86 | POLB (0.52) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL8902175 | 0.86 | CHEK1 (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL3975198 | 0.83 | PDGFRB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31430540 | 0.83 | PDGFRB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL30837492 | 0.83 | PDGFRB (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12108924 | 0.83 | PDGFRB (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL4854781 | 0.82 | GAA (0.59) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL6745891 | 0.82 | GAA (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL6749014 | 0.82 | PDGFRB (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-113166084-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4125883-A1 | COMBINATION THERAPY | Antabio SAS (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2022-04-14 | — | — | US | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| EP-3856730-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2021-08-04 | — | — | EP | disclosed |
| CN-113166084-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020064174-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ARG1, ELANE, INSR | PDGFRB 2505/4885FGFR1 819/4885PDGFRA 2361/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | PDGFRB 952/4885FGFR1 228/4885PDGFRA 767/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | PDGFRB 2744/4885FGFR1 757/4885PDGFRA 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.